Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + Tislelizumab + Radiotherapy + HAIC in HCC with Portal Vein Tumor Thrombus
ChiCTR2200056181Phase 4Recruiting
- Sponsor
- Xiamen University Zhongshan Hospital
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib and tislelizumab in hepatocellular carcinoma (HCC), sponsored by Xiamen University Zhongshan Hospital. Primary endpoints: Objective remission rate and Progression-free survival. Started Feb 2022; status: recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200056181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056181.